New look at fibrosis in scleroderma finds low levels of the antifibrotic protein, endostatin & Cathespin L. In vitro studies show a deficiency of Cathepsin L that should lead to its activation of antifibrotic endostatin - possibly a new Rx strategy for SSc https://t.co/qaLN0PVnLO https://t.co/TDK4sBZMV0